Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06029452 · ClinicalTrials.gov registry record
A Retrospective Validation Study To Identify Chart-Based Clinical Diagnosis Of Wild-Type Transthyretin Amyloid Cardiomyopathy (Attrwt-CM) And Non-Amyloid Heart Failure Among Patients With Heart Failure (HF).
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 558
- Enrollment target
NCT06029452 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 558 participants.
The verdict
NCT06029452 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 558 participants
- Enrollment target
Study Summary
This is an observational, retrospective non-inferiority study with a study sample from a large national database. A machine learning (ML) model will use a national database to predict the clinical diagnosis of ATTRwt-CM among HF patients. This study will include HF patients ≥50 years old.
Interventions
- OTHER Machine learning algorithm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 558 participants |
| Start Date | 2023-09-01 |
| Est. Completion | 2023-11-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06029452
The ClinicalTrials.gov registry entry for NCT06029452 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 558 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Machine learning algorithm is the first listed.
NCT06029452 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06029452 about?
NCT06029452 is a clinical study titled "A Retrospective Validation Study To Identify Chart-Based Clinical Diagnosis Of Wild-Type Transthyretin Amyloid Cardiomyopathy (Attrwt-CM) And Non-Amyloid Heart Failure Among Patients With Heart Failure (HF).". This is an observational, retrospective non-inferiority study with a study sample from a large national database. A machine learning (ML) model will use a national database to predict the clinical diagnosis of ATTRwt-CM among HF patients. This study will include HF patients ≥50 years old.
What is the current status of trial NCT06029452?
This trial is currently completed. The enrollment target is 558 participants. The study started on 2023-09-01. Estimated completion is 2023-11-14.
What interventions are being tested in trial NCT06029452?
The interventions under investigation include: Machine learning algorithm (OTHER).
Who is sponsoring clinical trial NCT06029452?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.